FIELD: medicine.
SUBSTANCE: invention aims at stating the presence of an infection in patients with acute manifested myeloid leukemia. It involves body temperature measurement, leukocyte, blast cell and C-reactive protein (CRP) count. If the CRP level is less than 12 mg/l, the infection is excepted. The CRP level more than 40 mg/l enables stating the presence of the infection regardless of leukocyte and blast cell count.
EFFECT: method enables early diagnosing of infectious complications in the acute disease state.
2 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| DIAGNOSTIC TECHNIQUE FOR INFECTION IN PATIENTS WITH MANIFESTED ACUTE LYMPHOBLASTIC LEUKAEMIA | 2013 |
|
RU2535057C1 |
| METHOD FOR DETECTION OF INFECTIOUS COMPLICATIONS IN PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKAEMIA ACCOMPANYING NEUTROPENIA | 2012 |
|
RU2497129C1 |
| METHOD OF DETERMINING EARLY LABORATORY MARKERS OF INFECTION GENERALISATION IN PATIENTS WITH ACUTE MYELOBLASTIC LEUKEMIA IN CASE OF NEUTROPENIA | 2008 |
|
RU2391671C2 |
| METHOD OF TREATING RECURRENT ACUTE MYELOID LEUKAEMIA FOLLOWING TRANSPLANTATION OF ALLOGENIC HAEMOPOIETIC STEM CELLS | 2013 |
|
RU2538799C1 |
| METHOD FOR PREDICTION OF DEVELOPING SEPSIS OR PNEUMONIA IN PATIENTS WITH ACUTE MYELOID LEUKAEMIA | 2024 |
|
RU2832525C1 |
| METHOD FOR PREDICTION OF DEVELOPING INFECTIOUS SYNDROME IN PATIENTS WITH ACUTE LEUKEMIA | 2013 |
|
RU2521372C1 |
| METHOD OF PREDICTING INFECTION DEVELOPMENT IN PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKAEMIA AT CHEMOTHERAPY BACKGROUND | 2014 |
|
RU2550967C1 |
| METHOD FOR PREVENTION OF DIARRHEA IN PATIENTS WITH ACUTE MYELOBLASTIC LEUKEMIA IN CASE OF AGRANULOCYTOSIS | 2018 |
|
RU2677279C1 |
| METHOD FOR DETERMINING EARLY PREDICTORS OF ONSET OF DIFFERENTIATION SYNDROME IN TREATING PATIENTS SUFFERING ACUTE PROMYELOCYTE LEUKEMIA | 2011 |
|
RU2461003C1 |
| DIAGNOSTIC TECHNIQUE FOR COMPLICATIONS OF VIRAL AND BACTERIAL AETIOLOGY IN PATIENTS WITH CHRONIC LYMPHATIC LEUKEMIA | 2019 |
|
RU2734670C1 |
